New Haven, CT, March 21, 2018 - Trevi Therapeutics, Inc. (“Trevi”), a late-stage clinical development company focused on developing Nalbuphine® ER for chronic pruritus (itch), today announced that Jennifer Good, President and Chief Executive Officer, will present at Needham & Company’s 17th Annual Healthcare Conference. The presentation will take place in New York City on Tuesday, March 27 at 4:30 pm ET.

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a late-stage clinical development company focused on developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. The Company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis.  Prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions (excoriative/ulcerative papules and nodules) on the skin. There are no approved therapies in the US or EU for this condition.

Nalbuphine® ER is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. Because of Nalbuphine® ER’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in both animal studies and human clinical trials, the Company believes Nalbuphine ER can have broad utility in treating chronic pruritus.

Founded in 2011, Trevi is headquartered in New Haven, CT.  For additional information, visit www.trevitherapeutics.com.